Eli Lilly and Company (SWX:LLY)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 715.96B +16.8% |
| Revenue (ttm) | 47.38B +45.4% |
| Net Income | 14.68B +120.0% |
| EPS | 16.30 +121.0% |
| Shares Out | n/a |
| PE Ratio | 48.77 |
| Forward PE | 32.65 |
| Dividend | 5.01 (0.63%) |
| Ex-Dividend Date | Nov 14, 2025 |
| Volume | n/a |
| Average Volume | 3 |
| Open | n/a |
| Previous Close | 780.00 |
| Day's Range | n/a |
| 52-Week Range | 538.08 - 880.00 |
| Beta | 0.33 |
| RSI | 40.68 |
| Earnings Date | Feb 4, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
Jim Cramer on what is driving Eli Lilly's stock right now
'Mad Money' host Jim Cramer looks ahead to next week's market moving moments.
Cramer's week ahead: Earnings from Eli Lilly, Alphabet and Amazon. Plus, jobs data
CNBC's Jim Cramer said Friday that the market's subdued finish to the week could be a good thing ahead of a busy earnings slate. AMD, Alphabet and Amazon are all set to report quarterly results.
Eli Lilly CEO says Medicare coverage of obesity drugs could 'change the game' for upcoming pill launch
Eli Lilly CEO Dave Ricks said upcoming Medicare coverage of obesity drugs could be a major catalyst for the launch of the company's closely watched experimental obesity pill, orforglipron. The launch ...
Eli Lilly to build $3.5 billion Pennsylvania plant in US manufacturing push
Eli Lilly announced on Friday that it will build a pharmaceutical manufacturing facility in Pennsylvania, its fourth new site in an effort to expand U.S. production and bolster medical supply chains.
Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections
Eli Lilly said it will spend $3.5 billion to build a manufacturing plant in Lehigh Valley, Pennsylvania, that will help make its next-generation obesity drugs. That includes a closely watched experime...
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility
The $3.5 billion Lehigh Valley site will develop Lilly's next-generation weight-loss medicines, including retatrutide Company plans to create more than 2,800 manufacturing and construction jobs at Lil...
Pennsylvania Wins Bid for Eli Lilly Weight-Loss Drug Factory
The region is attempting to build on its status as a manufacturing hub with bigger investments and more tax perks for corporate investors.
FDA Decision on Eli Lilly's Weight Loss Pill Delayed to Q2. Is This Bad News for the Stock?
Orforglipron is a promising weight loss pill that could be a huge growth catalyst for Eli Lilly. The Food and Drug Administration has pushed back the target action date on the drug by nearly two weeks...
Why Dividend Stocks Are Essential For What Comes Next
Why Dividend Stocks Are Essential For What Comes Next
Should You Buy Eli Lilly Before Feb. 4?
Eli Lilly will need an outstanding performance, likely driven by tirzepatide, to see its shares jump after its quarterly update on Feb. 4. Even if that doesn't happen, there are ample reasons to buy t...
Eli Lilly: Obesity Pricing For Access Tradeoff A Net Positive
Eli Lilly enters 2026 with strong commercial momentum, pipeline wins, and shares near all-time highs. The company's strategic price cuts for Zepbound and commitment to a low-priced launch of orforglip...
Eli Lilly Teams Up With Two Biotechs To Target Autoimmune Disease, Hearing Loss In Deals Worth $3 Billion
Repertoire Immune Medicines entered a strategic collaboration on Thursday with Eli Lilly and Co. (NYSE: LLY) to develop tolerizing therapies for multiple autoimmune diseases.
Trump says Eli Lilly to build six US plants
U.S. President Donald Trump said on Thursday that he has spoken to the head of pharmaceutical company Eli Lilly and that the company plans to build six plants in the country.
Prediction: Artificial Intelligence (AI) Will Reshape This Industry by 2030. This Stock Could Lead.
AI could make it faster and easier to develop drugs. Eli Lilly is looking to lead this transformation.
Lilly signs up to $1.93 billion deal with Repertoire for autoimmune therapies
Drugmaker Eli Lilly is partnering with Repertoire Immune Medicines in a deal worth up to $1.93 billion to develop therapies for multiple autoimmune diseases, the Massachusetts-based biotech said on Th...
Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless
U.S. drugmaker Eli Lilly signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the Germany-based startup said on Wednesday, to develop and commercialize treatments for hearing loss...
Exclusive: Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows
Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025, more than double what Eli Lilly shelled out for its rival medicines,...
US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
The U.S. Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs from major pharmaceutical companies including Eli Lilly , Pfizer and AbbVie for the third cycle of the M...
Up 36%, Is Eli Lilly Still a Buy?
Eli Lilly is at the forefront of both diabetes and obesity medications. The pharmaceutical giant has offered strong guidance for the end of 2025.
Where Will Eli Lilly Be in 10 Years?
The pharmaceutical industry has a well-structured cycle. Eli Lilly is currently benefiting from the early stages of the cycle.
Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker?
Both companies may succeed in this industry.
A Look Into Eli Lilly and Co Inc's Price Over Earnings
Looking into the current session, Eli Lilly and Co Inc. (NYSE: LLY) shares are trading at $1060.01, after a 0.40% drop. Over the past month, the stock decreased by 1.76% , but over the past year, it ...
Lansing Street Advisors Sells 138 Shares of Eli Lilly and Co (LLY)
Lansing Street Advisors Sells 138 Shares of Eli Lilly and Co (LLY)
BCS Wealth Management Sells 655 Shares of Eli Lilly and Co (LLY)
BCS Wealth Management Sells 655 Shares of Eli Lilly and Co (LLY)
Code Waechter LLC Buys 115 Shares of Eli Lilly and Co (LLY)
Code Waechter LLC Buys 115 Shares of Eli Lilly and Co (LLY)